Altimmune Inc
ALT3.630USD
+0.020+0.55%
Market hours （ET）Quotes delayed by 15 min
282.51MMarket Cap
LossP/E TTM
More Details of Altimmune Inc Company
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Company Info
Ticker SymbolALT
Company nameAltimmune Inc
IPO dateOct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Number of employees59
Security typeOrdinary Share
Fiscal year-endOct 06
Address910 Clopper Road
CityGAITHERSBURG
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code20878-1361
Phone12406541450
Websitehttps://altimmune.com/
Ticker SymbolALT
IPO dateOct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Mr. Philip L. Hodges
Mr. Philip L. Hodges
Independent Director
Independent Director
--
--
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Director
Director
--
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 29
Updated: Tue, Jul 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.43%
Investment Advisor/Hedge Fund
14.99%
Hedge Fund
8.48%
Research Firm
2.10%
Individual Investor
0.76%
Bank and Trust
0.36%
Pension Fund
0.23%
Insurance Company
0.04%
Other
51.61%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
412
39.48M
48.67%
-13.27M
2025Q1
433
39.51M
48.72%
-15.43M
2024Q4
439
41.91M
54.50%
-15.25M
2024Q3
440
40.83M
57.43%
-21.59M
2024Q2
436
43.67M
61.47%
-20.29M
2024Q1
418
45.76M
64.68%
-11.45M
2023Q4
387
34.44M
49.06%
-14.90M
2023Q3
368
31.34M
59.36%
-25.59M
2023Q2
362
36.16M
68.78%
-25.80M
2023Q1
371
44.34M
90.01%
-16.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.53M
6.82%
-133.00K
-2.35%
Mar 31, 2025
The Vanguard Group, Inc.
4.39M
5.42%
-24.15K
-0.55%
Mar 31, 2025
State Street Global Advisors (US)
3.39M
4.18%
-78.45K
-2.26%
Mar 31, 2025
Tang Capital Management, LLC
2.75M
3.39%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.71M
2.1%
+47.38K
+2.86%
Mar 31, 2025
Two Sigma Investments, LP
1.41M
1.74%
+741.11K
+110.45%
Mar 31, 2025
Columbia Threadneedle Investments (UK)
1.32M
1.63%
-3.78M
-74.03%
Mar 31, 2025
Marshall Wace LLP
1.17M
1.44%
+1.10M
+1683.26%
Mar 31, 2025
Knoll Capital Management, LLC
1.12M
1.38%
--
--
Mar 31, 2025
Millennium Management LLC
1.11M
1.37%
+765.66K
+221.52%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Roundhill GLP-1 & Weight Loss ETF
2.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.32%
Federated Hermes MDT Small Cap Core ETF
0.27%
Amplify Weight Loss Drug & Treatment ETF
0.22%
SPDR S&P Biotech ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.07%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
Invesco Nasdaq Biotechnology ETF
0.03%
View more
Roundhill GLP-1 & Weight Loss ETF
Proportion2.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.49%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.32%
Federated Hermes MDT Small Cap Core ETF
Proportion0.27%
Amplify Weight Loss Drug & Treatment ETF
Proportion0.22%
SPDR S&P Biotech ETF
Proportion0.1%
Fidelity Enhanced Small Cap ETF
Proportion0.07%
iShares Micro-Cap ETF
Proportion0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
